Vascepa's Status in Europe
Vascepa (icosapent ethyl) is not approved for any uses in the European Union by the European Medicines Agency (EMA). The EMA issued a negative opinion in 2020, rejecting marketing authorization for reducing cardiovascular risk in patients with high triglycerides despite statin therapy.[1]
Why EMA Rejected Vascepa
The EMA's Committee for Medicinal Products for Human Use (CHMP) determined that benefits did not outweigh risks, citing insufficient evidence from the REDUCE-IT trial on cardiovascular outcomes and concerns over trial design, including a high drop-out rate and imbalance in background therapies favoring Vascepa.[1][2]
Approvals Outside Europe
In contrast, the FDA approved Vascepa in the US:
- 2012: For severe hypertriglyceridemia (≥500 mg/dL).
- 2020: Expanded for cardiovascular risk reduction in high-risk patients on statins with triglycerides 135-499 mg/dL.[3]
No centralized EU approval exists, and individual member state approvals are unlikely without EMA nod.
Ongoing Efforts or Alternatives
Amarin, Vascepa's maker, withdrew its EU application post-rejection and has not refiled. Patients in Europe may access similar omega-3 therapies like Lovaza (also icosapent ethyl) under national approvals for hypertriglyceridemia, but not CV risk reduction.[4]
Patent and Market Insights
Vascepa faces patent expiry challenges globally; in Europe, related patents (e.g., EP2475423) expire around 2028-2030, but lack of approval limits relevance.[5]
[1]: EMA Assessment Report for Vascepa
[2]: EMA CHMP Opinion, July 2020
[3]: FDA Label for Vascepa
[4]: EMA Database Search for Icosapent Ethyl
[5]: DrugPatentWatch.com - Vascepa Patents